OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
about
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialSurgical resection of hepatic metastases from colorectal cancer: a systematic review of published studiesResection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomesColorectal cancer: Metastases to a single organRole of surgery in colorectal cancer liver metastasesCurrent approaches and challenges for monitoring treatment response in colon and rectal cancerColorectal Liver Metastases: A Critical Review of State of the ArtIs conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationPredictive and prognostic molecular markers for cancer medicineNeoadjuvant treatment for rectal cancer-A value-based proposition.Clinical significance of Neutrophil gelatinase-associated lipocalin(NGAL) expression in primary rectal cancer.Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer.Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008.Breast Implant-associated Anaplastic Large Cell Lymphoma: Updated Results from a Structured Expert Consultation Process.Medical treatment of advanced colorectal cancer in 2009.Novel methods for clinical risk stratification in patients with colorectal liver metastasesCancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomyInstitutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis.Curative strategies for liver metastases from colorectal cancer: a reviewPatterns of Care for Colorectal Liver Metastasis Within an Integrated Health System: Secular Trends and Outcomes.Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatmentSelective versus routine lymphadenectomy in the treatment of liver metastasis from colorectal cancer: a retrospective cohort studyAnti-inflammatory liposomes have no impact on liver regeneration in ratsIntegrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial FindingsResection of colorectal liver metastases: current perspectives.Postoperative mortality and need for transitional care following liver resection for metastatic disease in elderly patients: a population-level analysis of 4026 patients.The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trialOptimal treatment of metastatic colorectal cancer.Colorectal liver metastases: current and future perspectives.Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer.Metastatic colorectal cancer-past, progress and futureOptimizing the approach to patients with potentially resectable liver metastases from colorectal cancer.Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II studyLiver angulometry: a simple method to estimate liver volume and ratios.Accomplishments in 2008 in the management of curable metastatic colorectal cancer.Palliative treatment of unresectable metastatic colorectal cancer.
P2860
Q21261279-BAA02439-9B6A-4368-9F39-C7FE6ACA7263Q24651894-6A99AB3C-5F60-451D-8B0F-EF78150687E8Q26750691-C59BC71C-76D5-46B3-ADDB-A24098C717A2Q26778009-20FFD15C-4BCB-4444-A636-36F226BD4993Q26830444-A8D67ECA-F5BA-4929-B2D7-137C4EBB386EQ27010257-FE423E77-4211-4FB6-94A0-331841D84B0CQ28070400-6B9D0570-7F79-41FE-B48F-D947238373B0Q28084888-61196F42-0825-4C2A-A71E-EB15807DD51EQ28743108-A56A6FA9-2A34-474A-93AA-8B8DCD7489F1Q30251516-698593C1-B4C6-4BD1-BA38-05AF8F43DA9EQ33440034-59AEA5F5-118C-4425-9483-523BCB7DA091Q33710593-36D6BE3F-243B-42A4-B81F-9F9173B1469FQ33747440-052017D2-1398-4B74-83BA-456C9709A399Q34222890-37504FC2-9A3D-4298-BB11-CD162CA89B24Q34280511-EA5483F6-0059-485E-B288-C3CBF9C103A2Q34579685-B2BAF0CF-BDC4-4B7E-9EBB-C917E496CFEFQ35069314-7F3B513D-517C-4F92-882D-EB1DCDC9939EQ35076194-9736BBCB-D97B-4F47-9FCE-E1991066CBBDQ35429661-5D7E3459-8900-42CB-A8C6-E6D3E266B013Q35503680-83902165-8319-4714-962B-AADF0833D32CQ35602256-A003BA72-A3A2-4BC2-90D3-17A7FB13EEF2Q35653726-C9400CB3-4553-431B-98CA-A081A8349A0EQ35776233-12A6729A-BC56-4EDF-8ABA-3E09A510F474Q36061491-714FE4C9-0AFC-44CF-9B25-5C9AE0268BF6Q36253364-7870ACEB-FC7D-41DA-98B8-0049085531A7Q36334591-0374A818-2786-4BD9-9614-3DD231FE1498Q36387936-DBFEB81C-DD02-4A64-BDA7-658072C9BD1FQ36396031-3746FED4-E9C6-47C0-8B34-A3069FFAB05CQ36409950-7DB22D1C-4BBB-46C7-9F6B-DD1D4761E686Q36465704-025743CE-2AE5-43AE-BAE9-F0784ACDDA34Q36476152-41C38783-66CB-43B6-93E4-0022C04CF1B9Q36499255-3A963EF8-F7C4-4719-9F3F-C7FE14D73A83Q36572540-5187C5AA-C001-463C-A409-DCBC32ABCD25Q36842791-DA5D211A-2142-477C-9FDB-45C2C5DA6F11Q36893806-E5455E3D-C61A-4A64-BE0B-AAD2DB1F943BQ36968386-2A73D50C-0F1C-4C05-BA43-C82CBA55E14EQ37182234-3BAE113F-7389-409A-8CBC-E03B35FE79C1Q37350315-836097DD-82E8-4F35-8AE9-82C10CE04B26Q37468824-5E2A8D1F-03DE-46FF-B215-73AE68D608CBQ37650308-F741766A-B9E9-4B02-841A-7611F82DF5C6
P2860
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@ast
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@en
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@nl
type
label
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@ast
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@en
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@nl
prefLabel
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@ast
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@en
OncoSurge: a strategy for impr ...... metastatic colorectal cancer.
@nl
P2093
P356
P1476
OncoSurge: a strategy for impr ...... n metastatic colorectal cancer
@en
P2093
Bernard Nordlinger
Carlos Valls
Daniel Haller
Francis Kunstlinger
Gilles Mentha
Graeme J Poston
Hans Joachim Schmoll
James P Kahan
Juan Figueras
P304
P356
10.1200/JCO.2005.08.722
P407
P577
2005-10-01T00:00:00Z